RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > FDA’s Financial Disclosure Regulations: Careful Compliance in a Changing Landscape—Part I

FDA’s Financial Disclosure Regulations: Careful Compliance in a Changing Landscape—Part I

Posted 01 November 2010 | By

At first glance, compliance with US Food and Drug Administration (FDA) financial disclosure regulations set forth in 21 CFR Part 54 looks straightforward. The regulations are short, and the FDA guidance1 clarifies a number of issues. However, when faced with a mountain of invoices, financial data and contracts documenting financial ties to investigators and their institutions, trial sponsors often must make judgments about whether to disclose particular financial arrangements to FDA.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.